Targeted Intensification by a Preparative Regimen for Patients With High-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose BEAM [carmustine, etoposide, aracytine, melphalan] Followed by Autologous Stem Cell Transplantation (ASCT).

Trial Profile

Targeted Intensification by a Preparative Regimen for Patients With High-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose BEAM [carmustine, etoposide, aracytine, melphalan] Followed by Autologous Stem Cell Transplantation (ASCT).

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2015

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ZBEAM2
  • Most Recent Events

    • 11 Aug 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 28 Aug 2009 Trial phase changed from IV to II as reported by ClinicalTrials.gov.
    • 28 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top